Virtual EULAR Congress Aims for Patient-Inclusive Programming medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
ACCESSWIRE
11 May 2021, 20:05 GMT+10
Early identification of unique cell markers is expected to have valuable impact on patents, clinical efficacy, and manufacturing optimization
VANCOUVER, BC / ACCESSWIRE / May 11, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ( RepliCel or the Company ) is pleased to announce it has now signed and launched a new collaborative research project agreement with the University of British Columbia ( UBC ) that enables the second stage of its cell marker research. The project is being co-led by RepliCel s Dr. Kevin McElwee and UBC s Professor Youwen Zhou.
(1)
Early identification of unique cell markers is expected to have valuable impact on patents, clinical efficacy, and manufacturing optimization
VANCOUVER, BC / ACCESSWIRE / May 11, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ( RepliCel or the Company ) is pleased to announce it has now signed and launched a new collaborative research project agreement with the University of British Columbia ( UBC ) that enables the second stage of its cell marker research. The project is being co-led by RepliCel s Dr. Kevin McElwee and UBC s Professor Youwen Zhou.
The project commenced in 2017, is designed to deliver a gene and protein expression map of healthy hair follicle cells expected to be critically important to improving key components of the manufacturing, regulatory, and clinical profile of RepliCel s cell therapy products.
Studies Highlight Pandemic's Impact on Patients With RMDs medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Today s Medical Developments
Departments - Regulatory
Relivion wearable brain neuromodulation technology; Construx Mini Ti cervical spacer with Nanovate technology; Valkyrie Thoracic Fixation System from Able Medical Devices
Relivion wearable brain neuromodulation technology from
Neurolief is the first non-invasive multi-channel system for at-home treatment of acute migraines. Worn as a headset,
Relivion offers precise, personalized care by delivering stimulation to six branches of the occipital and trigeminal nerves via three adaptive output channels. This releases neurotransmitters in the brainstem and modulation of brain networks associated with pain control.
Developed to enhance anterior cervical discectomy and fusion (ACDF) procedures, the
Construx Mini Ti cervical spacer with Nanovate technology is the first 3D-printed titanium interbody introduced to the market by